RxDoctor Payments Data

Jordon Grube, DO

Otolaryngology/Facial Plastic Surgery · Albany, NYNPI 1114346566

Payments from drug & device makers

What this record shows

Aerin Medical Inc. accounts for 82.6% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $4,275, more than ten times the $34 reported in 2019.

$8,696in general payments, 2019–2025

Across 59 payments — averaging $147.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerin Medical Inc.$7K
  • Medtronic$506
  • Acclarent, Inc$340
  • Stryker$295
  • Integra Lifesciences Corporation$203
  • Optinose US, Inc.$135
  • plus $33 from 1 others

What the payments were for

  • Consulting fees$4,40051%
  • Food & beverage$4,29649%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Aerin Medical Inc.34$7,184
Medtronic(2 entities)10$506
Acclarent, Inc3$340
Stryker4$295
Integra Lifesciences Corporation2$203
Optinose US, Inc.5$135
Sanofi1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,696 in reported general payments places this provider in the 85th percentile of 48 otolaryngology/facial plastic surgery providers in New York.

See all otolaryngology/facial plastic surgery providers in New York

Medicare billing

Part B allowed, 2024
$93,003
Medicare patients
140
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate16$9,427
Budesonide46$7,096
Ipratropium Bromide89$3,261
Mometasone Furoate31$2,137
Fluticasone Propionate52$832
Doxycycline Monohydrate11$243
Prednisone48$177
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$135$9,42716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 otolaryngology/facial plastic surgery providers in New York.

Other otolaryngology/facial plastic surgery in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →